Adobe Names Anil Chakravarthy CEO as AI Push Accelerates 
OpenAI Nears Astra AI Model Launch With Safety Focus 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
Qantas Near-Miss Raises Sydney Air Traffic Controller Fatigue Concerns 
Volkswagen Approves 50,000 More Job Cuts in Major Restructuring 
Nvidia Eyes $2.5 Billion Investment in Thinking Machines Lab 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
Xiaomi Shares Jump on Europe EV Expansion Plan 
ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
Tesla Cybercab Rides Launch in Austin as NHTSA Reviews Rollout 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
Add as a preferred source on Google
DALLAS and FORT WORTH, Texas, March 08, 2018 -- Neos Therapeutics, Inc. (NASDAQ:NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing innovative extended-release (XR) products using its proprietary modified-release drug delivery and orally disintegrating tablet (ODT) technology platforms, today announced that it will report fourth quarter and year-end 2017 financial results prior to the opening of U.S. financial markets on Thursday, March 15, 2017. Neos management will host a conference call and live audio webcast to discuss these results and provide a company update at 8:30 a.m. ET that same day.
The live call may be accessed by dialing (877) 388-8985 for domestic calls, or +1 (562) 912-2654 for international callers, and referencing conference ID number 5653457. A live audio webcast for the conference call will be available on the Investor Relations page of the company’s website at http://investors.neostx.com/.
About Neos Therapeutics
Neos Therapeutics, Inc. (NASDAQ:NEOS) is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified-release drug delivery technology platforms. Adzenys XR-ODT® (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING), Cotempla XR-ODT™ (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING), and Adzenys-ER™ (amphetamine) extended-release oral suspension (see Full Prescribing Information, including Boxed WARNING), all for the treatment of ADHD, are the first three approved products using the Company’s extended-release technology platform. Additional information about Neos is available at www.neostx.com.
Contacts:
Richard Eisenstadt
Chief Financial Officer
Neos Therapeutics
(972) 408-1389
[email protected]
Sarah McCabe
Senior Vice President
Stern Investor Relations, Inc.
(212) 362-1200
[email protected]
